Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
October 26, 2023 15:19 ET
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for...
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
September 21, 2023 08:00 ET
|
Benitec Biopharma Inc.
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD...
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
July 19, 2023 06:00 ET
|
Catalyst Pharmaceuticals, Inc.
Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters...
Muscular Dystrophy Association Celebrates FDA Approval of Sarepta Therapeutics’ ELEVIDYS for Treatment of Duchenne Muscular Dystrophy
June 22, 2023 15:31 ET
|
Muscular Dystrophy Association
New York, June 22, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene...
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
June 20, 2023 06:00 ET
|
Catalyst Pharmaceuticals, Inc.
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan...
CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy Announce Collaborative Project to Focus on Re-Dosing Gene Therapy in Duchenne Muscular Dystrophy
June 15, 2023 14:43 ET
|
Muscular Dystrophy Association
New York, June 15, 2023 (GLOBE NEWSWIRE) -- June 15, 2023 -- CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative...
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
May 30, 2023 05:00 ET
|
AKAMPION
FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)DMD is a designated orphan disease in both Europe and the...
MDA Launches Pinup & Roundup Campaigns at Thousands of Retail Partner Locations Nationwide to Fund Summer Camp for Kids and Young Adults 8-17 Living with Muscular Dystrophy & Related Neuromuscular Diseases
May 25, 2023 11:21 ET
|
Muscular Dystrophy Association
New York, May 25, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) today announced over 1,000 retail partner locations nationwide are participating with customer pinup, roundup or...
Muscular Dystrophy Association Announces Gene Therapy Support Network for Families Living with Neuromuscular Disease
May 22, 2023 14:48 ET
|
Muscular Dystrophy Association
New York, May 22, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) announced today the launch of the MDA Gene Therapy Support Network (GTx), ahead of a pending FDA approval for the...
Muscular Dystrophy Association Tribute Awards in Washington D.C. Honor Diana X. Bharucha-Goebel, M.D., R. Rodney Howell, M.D., Paul Robertson, Jeni Stepanek, Ph.D., Janet Woodcock, M.D.
May 11, 2023 11:55 ET
|
Muscular Dystrophy Association
New York, NY, May 11, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) Tribute Awards will be held in Washington D.C. to honor: Diana X. Bharucha-Goebel, M.D., Associate Professor,...